Subscribe to Money Morning get daily headlines subscribe now! Money Morning Private Briefing today's private briefing Access Your Profit Alerts

EpiPen's Biggest Rival Is Back – and It's Shining a New Light on an Emerging $21 Billion Market

For the past year, we've been telling you about the allergy pandemic: that allergies are a growing global challenge - and that the growth in number of sufferers is being exacerbated by an increasing complexity in the types of allergies doctors must treat.

There's an important reason we keep coming back to this.

You see, when I refer to "allergies," I'm not talking just about hives and a bit of scratchiness. I'm focusing on health-destabilizing reactions or the life-threatening allergen response known as anaphylaxis.

Leave a Reply

Your email address will not be published. Required fields are marked *

Some HTML is OK